France's Cellectis wins U.S patents for gene editing technology
February 13, 2018 at 00:00 AM EST
PARIS, Feb 13 (Reuters) - The United States has granted French cell therapy group Cellectis two patents to deploy a technology known as CRISPR in T cells, which play a key role in the immune response to cancer, the company said on Tuesday.
